

OPHTHOTECH CORP.

FORM 8-K/A (Amended Current report filing)

Filed 03/31/17 for the Period Ending 06/02/16

Address	ONE PENN PLAZA 19TH FLOOR NEW YORK, NY 10119
Telephone	212-845-8200
CIK	0001410939
Symbol	OPHT
SIC Code	2834 - Pharmaceutical Preparations
Industry	Biotechnology & Medical Research
Sector	Healthcare
Fiscal Year	12/31

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 8-K/A

Amendment No. 1 to Form 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **June 2, 2016**

OPHTHOTECH CORPORATION
(Exact Name of Registrant as Specified in Charter)

Delaware
(State or Other Jurisdiction
of Incorporation)

001-36080
(Commission
File Number)

20-8185347
(I.R.S. Employer
Identification No.)

One Penn Plaza, 19th Floor
New York, New York 10119
(Address of Principal Executive Offices) (Zip Code)

Registrant's telephone number, including area code: **(212) 845-8200**

Not Applicable
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-
-
-

Explanatory Note

This Amendment No. 1 on Form 8-K/A amends the Current Report on Form 8-K filed on June 8, 2016 (the “Original Filing”) by Ophthotech Corporation (the “Company”). The Original Filing reported, among other items, the final voting results of the Company’s Annual Meeting of Stockholders held on June 2, 2016 (the “Annual Meeting”). The sole purpose of this amendment is to disclose, as required by U.S. Securities and Exchange Commission regulations, the Company’s decision regarding the frequency of future shareholder advisory votes on the compensation of its named executive officers. Other than as set forth in Item 5.07 below, no other disclosure in the Original Filing is amended by this Form 8-K/A.

Item 5.07. Submission of Matters to a Vote of Security Holders.

As reported in the Original Filing, at the Annual Meeting, in accordance with the recommendation of the Board of Directors, the Company’s stockholders recommended, by advisory vote, a one-year frequency of future advisory votes on the compensation of the Company’s named executive officers. In accordance with these results and its previous recommendation, the Board of Directors determined that future advisory votes on named executive officer compensation will be held every year until the next required advisory vote on the frequency of shareholder votes on executive compensation.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

OPHTHOTECH CORPORATION

Date: March 31, 2017

By: /s/ Glenn P. Sblendorio

Glenn P. Sblendorio

President, Chief Financial Officer and Treasurer